HAL (France)open access
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
Osimertinib resistance, 0, Non-small cell lung cancer NSCLC, Tyrosine kinase inhibitors TKIs re-challenge, Treatment strategy, Epidermal growth factor receptor EGFR L718Q
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 818550
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.